Tag Archives: Amylin

Diabetes Drug Launch 2012: Tip-tops and Promo-flops

By Clark Herman | Published: October 12, 2012

With Halloween candy flooding the shelves in pharmacies across the nation, it’s only appropriate that we turn the conversation toward an ever-growing drug market and therapeutic area: diabetes.

Posted in Advertising, E-Media, FDA, Marketing, Meetings, Strategy | Also tagged Boehringer Ingelheim, Eli Lilly, Launch, Merck, Professional Marketing | 1 Comment

Amylin Drops 200 Sales Reps

By George Koroneos | Published: May 6, 2009

Image via Wikipedia Biotech firm Amylin, on Monday, announced that it would trim its sales force by 200, or about 35 percent of its total. The move is expected to save the company about $65 million by 2010, and comes on the heels of an announcement that the company asked FDA to consider a once-weekly injectable [...]

Posted in Strategy | Also tagged Amylin Pharmaceuticals, Byetta, Eli Lilly, Eli Lilly and Company, Exenatide, GlaxoSmithKline, U.S. Food and Drug Administration | Leave a comment